Â鶹´«Ã½

  • By clicking "OK" or continuing to use this site, you agree that we may collect and use your personal data and set cookies to improve your experience and customise advertising. To see how, and to learn how to control cookies, please read our Privacy Policy and Cookie Policy.
OK
Advertisement
Pharmaceutical Technology18:45mRNA Coronavirus Vaccine Japan
Pharmaceutical Business Review12:34Moderna Vaccine Coronavirus Vaccine MHRA
European Pharmaceutical Manufacturer13:10Covid Treatment Coronavirus Vaccine Science
The Conversation (UK)21:38Covid WHO Australia
In the last 4 hours
Skeptical Raptor22:17 19-Sep-24
In the last 7 days
Pharmaceutical Technology18:45 13-Sep-24
PR Newswire (Press Release)14:28 13-Sep-24
Business Wire (Press Release)13:08 13-Sep-24
In the last month
Medical Xpress16:57 10-Sep-24
PR Newswire (Press Release)15:10 10-Sep-24
The Conversation (UK)21:38 9-Sep-24
Zacks14:08 6-Sep-24
Pharmaceutical Business Review11:55 6-Sep-24
European Pharmaceutical Manufacturer13:10 5-Sep-24
European Pharmaceutical Manufacturer13:15 4-Sep-24
Pharmaceutical Business Review12:34 4-Sep-24
PMLiVE12:26 4-Sep-24
ABC Online20:35 3-Sep-24
Benzinga14:46 3-Sep-24
GOV.UK (Press Release)13:09 3-Sep-24
PMLiVE12:33 3-Sep-24
Pharmaceutical Technology16:51 2-Sep-24
Pharmacy Times16:17 2-Sep-24
Pharmaceutical Field11:48 2-Sep-24
NBC Connecticut21:34 30-Aug-24
Forbes21:14 30-Aug-24
Novavax (Press Release)20:56 30-Aug-24
Mint20:30 30-Aug-24
Korea Biomedical Review07:23 30-Aug-24
AsiaOne02:05 24-Aug-24
GlobeNewswire (Press Release)19:19 22-Aug-24
view more headlines
19 Sep 22:17

About our JN.1 news

Latest news on the JN.1 COVID-19 variant: stay up-to-date with the developments of the JN.1 variant through Â鶹´«Ã½'s focused feed.

The JN.1 COVID-19 variant, a subvariant of the Omicron lineage BA.2.86, is currently under close monitoring by public health agencies worldwide due to its increased transmission rate. It first emerged in the United States in September and has since spread to multiple countries, including the UK.

Our JN.1 dedicated feed offers comprehensive insights into the evolution, spread, and impact of this new subvariant of the SARS-CoV-2 virus, which is closely monitored by global health organisations. It is a crucial tool for health professionals, researchers, policymakers, and anyone keen on understanding the dynamics of this emerging health challenge.

Our coverage delves into various aspects of JN.1, including its transmissibility, the effectiveness of current vaccines against it, and the public health responses being adopted globally. We explore in-depth analyses of JN.1's genetic mutations, how it compares with previous COVID-19 variants, and its implications for future virus management strategies. The feed also looks at the variant's global spread, with specific attention to its impact in countries like the United States and the UK, providing a nuanced perspective on the variant's progression and the concerted efforts to contain it.

For those following pandemic trends, healthcare experts, and those interested in public health developments, Â鶹´«Ã½'s feed on the JN.1 variant is an indispensable resource. We compile the latest news, expert analyses, and comprehensive reports from reliable sources, offering a thorough and balanced view of the evolving situation surrounding the JN.1 COVID-19 variant.


Publication filters

Headline Density

Sorry, no headlines or news topics were found. Please try different keywords.